Health Trials

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

ConditionPulmonary Arterial Hypertension PAH
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

About this trial

This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy

Eligibility criteria

Qualifiers

Participants aged 18-75 years old (inclusive), any gender;

Idiopathic PAH;

Heritable PAH;

Drug- or toxin-induced PAH;

Disqualifiers

HIV-associated PAH

Portal hypertension-associated PAH

Schistosomiasis-associated PAH

PAH associated with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis

Trial design

Treatments tested in this trial

  • IMC-003 and PAH background therapy
  • IMC-003 placebo and PAH background therapy

Treatment groups

120 Participants
are divided into 2 treatment groups

Sponsors and collaborators

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Lead sponsor

Source ClinicalTrials.gov